Please use this identifier to cite or link to this item:
|Type:||Artigo de periódico|
|Title:||Pulmonary Deposition Of Inhaled Tobramycin Prior To And After Respiratory Therapy And Use Of Inhaled Albuterol In Cystic Fibrosis Patients Colonized With Pseudomonas Aeruginosa [deposição Pulmonar De Tobramicina Inalatória Antes E Após Fisioterapia Respiratória E Uso De Salbutamol Inalatório Em Pacientes Com Fibrose Cística Colonizados Por Pseudomonas Aeruginosa]|
De Sa Camargo Etchebere E.C.
De Oliveira Ribeiro M.A.G.
|Abstract:||Objective: To evaluate whether respiratory therapy followed by the use of inhaled albuterol modifies the pulmonary deposition of inhaled tobramycin in patients with cystic fibrosis (CF) and whether pulmonary deposition correlates with disease severity or genotype. Methods: A prospective study was carried out including patients with CF older than 6 years of age and colonized with Pseudomonas aeruginosa. Exclusion criteria were pulmonary exacerbation, changes in therapy between the study phases and FEV1 < 25%. All patients were submitted to pulmonary scintigraphy by means of a scintillation camera equipped with a low-energy all-purpose collimator in order to evaluate drug penetration following the administration of inhaled 99mTc-tobramycin, as well as to pulmonary perfusion with 99mTc-macroaggregated albumin (phase 1). One month later, the same procedure was performed following respiratory therapy and administration of inhaled albuterol (phase 2). Results: We included 24 patients (12 males) aged 5-27 years (mean ± SD: 12.85 ± 6.64 years). The Shwachman score (SS) was excellent/good in 8 patients, moderate/fair in 16 and poor in 0. Genotyping revealed that 7 patients were ΔF508 homozygotes, 13 were ΔF508 heterozygotes; and 4 presented other mutations. In all patients, lung deposition of tobramycin decreased in phase 2, especially in those with moderate/fair SS (p = 0.017) and in heterozygotes (p = 0.043). Conclusions: The use of a respiratory therapy technique and the administration of inhaled albuterol immediately prior to the use of inhaled tobramycin decreased the pulmonary deposition of the latter in CF patients, and this reduction correlates with disease severity and genotype.|
|Appears in Collections:||Unicamp - Artigos e Outros Documentos|
Files in This Item:
|2-s2.0-61449154606p.pdf||342.62 kB||Adobe PDF||View/Open|
|2-s2.0-61449154606i.pdf||342.44 kB||Adobe PDF||View/Open|
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.